New and recently funded Medical Startups
1
Country: USA | Funding: $219.3M
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
Garner Health is a provider of healthcare services used to help employers give their employees a better healthcare experience.
2
Country: USA | Funding: $452M
Talkiatry is a virtual mental health care platform with over 800 full-time psychiatrists. These specialists provide care for a variety of conditions, including anxiety, depression, insomnia, mood disorders, postpartum depression, pediatric mental health, bipolar disorder, OCD, PTSD and substance use disorders. Their work is powered by AI platform that facilitates interaction with patients between visits and monitors the quality and level of care provided. The startup also implements innovative payment models with insurance companies.
Talkiatry is a virtual mental health care platform with over 800 full-time psychiatrists. These specialists provide care for a variety of conditions, including anxiety, depression, insomnia, mood disorders, postpartum depression, pediatric mental health, bipolar disorder, OCD, PTSD and substance use disorders. Their work is powered by AI platform that facilitates interaction with patients between visits and monitors the quality and level of care provided. The startup also implements innovative payment models with insurance companies.
3
Country: USA | Funding: $2.8B
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
Exact Sciences creates noninvasive screening tests for the early detection of cancer. The company's flagship product, Cologuard test, uses a biomarker panel that analyzes a stool sample for 10 DNA markers, as well as fecal blood (hemoglobin). It detects colon cancer even in its early stages, when it is more treatable. The test can be administered at home without special training. Cologuard includes a built-in patient management program with support. The test is based on proprietary QuARTS (quantitative allele-specific amplification of target and real-time signal) technology, which efficiently amplifies and quantifies two distinct methylated DNA markers (NDRG4 and BMP3), as well as seven different point mutations of the KRAS gene. The beta-actin gene (ACTB) serves as a reference marker for quantifying the total amount of human DNA in each sample.
4
Country: India
SkinBB is a science-driven skintech ecosystem designed to strengthen skincare choices through knowledge, not marketing claims. It blends AI, dermatology, and community voices to decode products, explain skin concerns, and guide real decisions. Every feature - from ingredient analysis to expert content - works toward one goal: helping users Apply Knowledge to Skin with clarity, confidence, and transparency.
SkinBB is a science-driven skintech ecosystem designed to strengthen skincare choices through knowledge, not marketing claims. It blends AI, dermatology, and community voices to decode products, explain skin concerns, and guide real decisions. Every feature - from ingredient analysis to expert content - works toward one goal: helping users Apply Knowledge to Skin with clarity, confidence, and transparency.
5
Country: Israel | Funding: $415.4K
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
UB Therapeutics is developing new therapy for the treatment of multiple myeloma. It's candidate, proteasome degradation inhibitor, has shown great promise in early preclinical studies. It differs from other proteasome inhibitors in that it more directly targets the proteasome degradation pathway, potentially leading to increased efficacy in patients who have developed resistance to other FDA-approved proteasome inhibitors. The compound is a cyclic peptide with potential anticancer therapeutic activity, blocking the action of deubiquitinases and the proteasome, inducing apoptosis in vitro, and attenuating tumor growth in vivo. This distinct mechanism may have therapeutic advantages as it avoids the innate and acquired resistance associated with direct proteasome inhibitors.
6
Country: Australia | Funding: A$10M
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
HaemaLogiX develops novel immuno-oncology and immunotherapy drugs for the treatment of blood cancers and B-cell diseases. Unlike existing treatments, HaemaLogiX products preserve the patient's immune system, helping fight cancer and maintain resistance to life-threatening infections during treatment. HaemaLogiX drugs are monoclonal antibodies that bind to unused and unique targets - KMA (kappa myeloma antigen) and LMA (lambda myeloma antigen) antigens - which are absent on normal plasma cells. The company is also developing KMA.CAR-T cell therapy, designed for separate subsets of multiple myeloma patients to KappaMab who have become resistant to standard treatments. The binding arm of KappaMab is connected to two proteins inside the T cell that are capable of stimulating and signalling to the T cell that it should destroy the KMA-positive myeloma cell.
7
Country: UK | Funding: $60M
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
8
Country: Canada
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
9
Country: USA | Funding: $335.4M
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
10
Country: Chile | Funding: $1.1M
Ilico Genetics is a subsidiary of the Pontificia Universidad Católica de Chile, that developed GastroMDx - liquid biopsy test for the early detection of gastric cancer. According to the company, it is the first methylated DNA-based molecular test specifically designed for the early detection of gastric cancer - detecting the disease years before the current "gold standard" esophagogastroduodenoscopy (EGD) can detect it. GastroMDx uses molecular biomarkers based on genetic and epigenetic signatures - subtle changes in DNA or RNA expression patterns - that can indicate the early presence of malignancy.
Ilico Genetics is a subsidiary of the Pontificia Universidad Católica de Chile, that developed GastroMDx - liquid biopsy test for the early detection of gastric cancer. According to the company, it is the first methylated DNA-based molecular test specifically designed for the early detection of gastric cancer - detecting the disease years before the current "gold standard" esophagogastroduodenoscopy (EGD) can detect it. GastroMDx uses molecular biomarkers based on genetic and epigenetic signatures - subtle changes in DNA or RNA expression patterns - that can indicate the early presence of malignancy.
